The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Next steps in myeloma: quadruplets, immunotherapy, and replacing transplant
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, talks on the future of multiple myeloma management, highlighting the promise of quadruplet regimens. Several recent trials, including the GRIFFIN trial (NCT02874742) of daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd), and the MASTER trial (NCT03224507) of daratumumab, lenalidomide, carfilzomib, and dexamethasone (D-KRd), have demonstrated the strong clinical activity of these combinations. Dr Fonseca notes that how to follow quadruplets is an unanswered question. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
